Lanreotid Viatris (Lanreotide)

Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptor subtypes 2 and 5 on target cells. This binding activates inhibitory signaling pathways that lower cyclic AMP and calcium influx, leading to decreased release of growth hormone, insulin‑like growth factor‑1, and other peptide hormones produced by neuroendocrine tumors.

The dosing regimen for Lanreotid Viatris is individualized and determined by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. Healthcare providers select the appropriate dose and injection interval according to current clinical guidelines and patient-specific factors.

Safety data for lanreotide in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risk‑benefit profile with their healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After receipt, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain where applicable) and any required import documentation.

The primary alternative to lanreotide is octreotide, another somatostatin analogue. Both agents inhibit hormone secretion, but lanreotide has a longer dosing interval (often every 4‑8 weeks) compared with octreotide’s more frequent dosing schedule. Clinical efficacy is comparable, while the choice often depends on patient convenience, tolerability, and physician preference.

Lanreotid Viatris should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 minutes before administration.

The medication is supplied as a sterile solution for subcutaneous injection. A healthcare professional administers the dose using a pre‑filled syringe or autoinjector, typically into the abdominal wall or thigh. Injection frequency is determined by the prescriber, commonly ranging from every four to eight weeks depending on the indication and patient response.

Serious adverse events include gallbladder disease such as cholelithiasis, pancreatitis, and significant hyperglycemia that may require adjustment of antidiabetic therapy. Cardiovascular effects like bradyarrhythmias have also been reported. Patients should be monitored for abdominal pain, jaundice, unexplained hyperglycemia, or any signs of cardiac rhythm disturbances.

Lanreotide is contraindicated in individuals with known hypersensitivity to lanreotide or any of the formulation excipients. Caution is advised for patients with severe uncontrolled diabetes, active gallbladder disease, or significant hepatic impairment. Pregnant or nursing women should only use it when the potential benefit outweighs the potential risk.